NCT07197307 - Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

January 15, 2030

Study Completion Date

January 15, 2030

Conditions

Aggressive Diffuse Large B-cell LymphomaHigh-grade B-cell Lymphoma (HGBL)Follicular Lymphoma (FL) Grade 3B

Interventions

DRUG

Loncastuximab Tesirine and Epcoritamab

Combination therapy of loncastuximab tesirine and epcoritamab

Trial Locations (1)

Universitätsklinikum Münster, Medizinische Klinik A, Münster